India's Glenmark Gets Arbitrator Nod to Sell HIV-Associated Diarrhea Drug

The International Center for Dispute Resolution has ruled that India's Glenmark Pharmaceuticals has the right to sell Crofelemer, its drug for HIV-associated diarrhea, in 140 countries. The medication was developed by Glenmark with U.S.-based partners Napo Pharmaceuticals and Salix Pharmaceuticals Ltd. Glenmark sought arbitration in the United States in December, after Napo terminated a three-party agreement that gave Glenmark exclusive distribution rights for Crofelemer in India and 139 other nations. In a statement, Glenmark said the ICDR found that Napo breached the agreement by revealing confidential information about manufacturing Crofelemer to Aptuit Laurus, another drugmaker. Glenn Saldanha, Glenmark's chair, said the ruling will permit the company "to further its commitment to working with relief agencies to distribute Crofelemer to affected populations."

Back to other news for September 2012